Clinical Trial to Evaluate the Safety of Continuous IV Tirofiban in Acute Ischemic Stroke

Inclusion Criteria: * Age ≥ 18 and ≤ 90 years * Acute ischemic stroke (AIS) * Onset of AIS 6-24 hrs. * NIHSS score ≥ 6 * AIS due to LVO * core infarct \<30cc or ASPECT score \> 6. * Received MT per SOC * TICI score of 2B, or TC post MT. * Able to be imaged by MRI * Patient or their Legally Authorized Representative (LAR) has provided written informed consent. Exclusion Criteria: * Known allergy or hypersensitivity to tirofiban * Previous stroke in the past 90 days * Previous intracranial hemorrhage, neoplasm, subarachnoid hemorrhage, or arterial venous malformation * Clinical presentation suggested a subarachnoid hemorrhage, even if initial CT scan was normal * Surgery or biopsy of parenchymal organ in the past 30 days * Trauma with internal injuries or ulcerative wounds in the past 30 days * Severe head trauma in the past 90 days * Systolic blood pressure persistently \>180mmHg post-MT despite antihypertensive intervention. * Diastolic blood pressure persistently \>105mmHg post-MT despite antihypertensive intervention. * Serious systemic hemorrhage in the past 30 days. * Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency, or oral anticoagulant therapy with INR \>1.5 * Positive urine pregnancy test for women of childbearing potential * Glucose \<50 or \>400 mg/dl * Platelets \<100,000/mm3 * Hematocrit \<25 % * Elevated PTT above laboratory upper limit of normal * Creatinine \> 4 mg/dl * Ongoing renal dialysis, regardless of creatinine * Received Low Molecular Weight heparins (such as Dalteparin, Enoxaparin, Tinzaparin) in full dose within the previous 24 hours * Abnormal PTT within 48 hours prior to randomization after receiving heparin or a direct thrombin inhibitor (such as bivalirudin, argatroban, dabigatran or lepirudin) * Received Factor Xa inhibitors (such as Fondaparinux, apixaban or rivaroxaban) within the past 48 hours * Received iv tPA * Pre-existing neurological or psychiatric disease which confounded the neurological or functional evaluations e.g., baseline modified Rankin score \>3 * Other serious, advanced, or terminal illness or any other condition that the investigator felt would pose a significant hazard to the patient if tirofiban therapy was initiated a. Example: known cirrhosis or clinically significant hepatic disease * Current participation in another research drug treatment or interventional device trial * Informed consent from the patient or the legally authorized representative was not or could not be obtained * High density lesion consistent with hemorrhage of any degree * ASPECT score \< 6 * Deployment of a stent INTRA and/or EXTRA-cranial * Did not receive MT * TICI score of 3 post MT * Extravasation of contrast during procedure * Perforation of any vessel during procedure. * Renal dysfunction * History of gastrointestinal hemorrhage or major systemic hemorrhage within 30 days, hemoglobin less than 8 g/dL on admission, INR ≥1.5, severe liver impairment as defined as AST, ALT, AP, GGT \> 2 x normal * Creatinine clearance \<30 mL/min. * Major surgery within 30 days with contra-indication to antiplatelet therapy * Currently pregnant. * Contraindication for MRI * Contra-indication to antiplatelet tirofiban: 1. Active internal bleeding or a history of bleeding diathesis within the previous 30 days 2. History of thrombocytopenia following prior exposure to AGGRASTAT 3. History, symptoms, or findings suggestive of aortic dissection 4. Acute pericarditis * Actual Body Weight \>150kg (due to the lack of safety data)